Carfilzomib prevented BCMA degradation, increased target density, and improved CAR T susceptibility by ~26%–28% in vitro, while enhancing xenograft antitumor activity without worsening T-cell ...
The U.S. Food and Drug Administration (FDA) has accepted a new drug application for iberdomide combined with Darzalex ...
Hepta refractory multiple myeloma is marked by antigen loss, genomic complexity, and 12.8 month median survival in multi centre data.
The FDA has started a priority review of iberdomide as an add-on to Johnson & Johnson and Genmab's anti-CD38 antibody Darzalex (daratumumab) and dexamethasone, a standard regimen for relapsed or ...
C4 Therapeutics, Inc. (NASDAQ:CCCC) is included in our list of the 7 most volatile stocks under $5 for day trading. As of ...
FDA has accepted the NDA for BMS's Iberdomide, an oral agent targetting relapsed/refractory multiple myeloma.
Nocturnal symptoms and musculoskeletal pain are filtered through relapse fear, driving repetitive interpretation of ...
Iberdomide has the potential to be the first approved CELMoD agentThe U.S. FDA has granted Breakthrough Therapy Designation and Priority Review for this indication and assigned a target action date of ...
Rheumatologist Dr Thomas Batty and haematologist Dr Emma Conway O'Brien describe a rational approach to investigating multifocal pain ...
Home > Pressemitteilung: Multiple myeloma: Established cancer ...
Princeton, New Jersey Thursday, February 19, 2026, 11:00 Hrs [IST] ...
Jaime Suarez-Londono, MD: Transplant for myeloma is very easy to give. On day 12 they engraft and they go home. Adverse events are not that [severe], and they get this progression-free survival [PFS] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results